TY - JOUR T1 - The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial JO - Blood PY - 2013/11/15 AU - Ashcroft J AU - de Tute RM AU - Cairns DA AU - Fletcher M AU - Owen RG AU - Rawstron A AU - O'Connor SJM AU - Williams CD AU - Snowden JA AU - Cavenagh JD AU - Parrish C et al ED - DO - DOI: 10.1182/blood.v122.21.3378.3378 PB - American Society of Hematology VL - 122 IS - 21 SP - 3378 EP - 3378 Y2 - 2024/12/28 ER -